Browsing Closed Research Teams by author "Harrington, Kevin"
Now showing items 1-4 of 4
-
Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley, TA; Da Pieve, C; Martins, CD; Ciobota, DM; Allott, L; et al. (SOC NUCLEAR MEDICINE INC, 2019-03-01)In head and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. So far, cetuximab is the only approved anti-EGFR monoclonal ... -
An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
Henderson, DR; Murray, JR; Gulliford, SL; Tree, AC; Harrington, KJ; et al. (ELSEVIER SCIENCE LONDON, 2018-09-01)AIMS: There are limited data on dosimetric correlates of toxicity in stereotactic body radiotherapy (SBRT) for prostate cancer. We aimed to identify potential relationships between dose and toxicity using conventional ... -
Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning.
Guerreiro, F; Burgos, N; Dunlop, A; Wong, K; Petkar, I; et al. (ELSEVIER SCI LTD, 2017-03-01)BACKGROUND AND PURPOSE: Computed tomography (CT) imaging is the current gold standard for radiotherapy treatment planning (RTP). The establishment of a magnetic resonance imaging (MRI) only RTP workflow requires the ... -
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; et al. (AMER ASSOC CANCER RESEARCH, 2018-04-15)Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...